Robert Uger, Chief Scientific Officer at Trillium Therapeutics Inc. (TRIL), sold 13,710 shares at $12.65 ($174K) on 2021-02-08, disclosed to the SEC on 2021-02-10.
Open-market sale of $174k TRIL by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.65 | 6,563 | $83K | 47.6% |
| 2 | $12.65 | 6,563 | $83K | 47.6% |
| 3 | $14.12 | 584 | $8K | 4.7% |
| Total | $12.71 avg | 13,710 | $174K | 100% |
| Filing → |
| TRIL | SELL | 2021-05-11 | $34K | — | Filing → |
| TRIL | SELL | 2021-04-09 | $39K | — | Filing → |
| TRIL | SELL | 2021-03-15 | $35K | — | Filing → |